Cel­gene sub­mits EU mar­ket­ing pitch for lus­pa­ter­cept; Bausch Health wins FDA ap­proval for top­i­cal pso­ri­a­sis treat­ment

→ Cel­gene and part­ner Ac­celeron have sub­mit­ted an EU mar­ket­ing ap­pli­ca­tion for their their red blood cell boost­ing drug lus­pa­ter­cept weeks af­ter sub­mit­ting an FDA mar­ket­ing ap­pli­ca­tion for the bi­o­log­ic. For the big biotech $CELG, tar­nished by a poor per­for­mance un­der CEO Mark Alles — the drug is one of the top five in its pipeline, crit­i­cal for the mighty $74 bil­lion Bris­tol-My­ers Squibb $BMY takeover.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER